Spain· ES:1201476001
ADAKVEO 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION
A crizanlizumab product containing crizanlizumab, registered in Spain by Novartis Europharm Limited. The same ATC class is registered in 7 of our 19 countries.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
Where it is registered
Crizanlizumab is registered in 7 of 19 countries.
Countries holding a registration under ATC B06AX01 (crizanlizumab), each read from that country’s own register.
- This record: Spain, from AEMPS CIMA (Spain)
- 6 of them publish a price we can compare per daily dose
Crizanlizumab · ATC B06AX01
7 / 19 countries
- Belgiumprice
- Finlandprice
- Franceprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- Crizanlizumab
- Manufacturer
- Novartis Europharm Limited
- Country
- Spain (ES)
- ATC code
- B06AX01
- ATC class
- Crizanlizumab
- Defined daily dose
- 12.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Crizanlizumab in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesADAKVEONovartis Pharmaceuticals Corporation
- BelgiumAdakveo 10 mg/mlNovartis Europharm
- FinlandAdakveoNovartis Europharm Limited
- FranceADAKVEO 10 mg/mL, solution à diluer pour perfusionNOVARTIS EUROPHARM (IRLANDE)
- United KingdomAdakveo 100mg/10ml concentrate for solution for infusion vialsNovartis Pharmaceuticals UK Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7d044a56-11e6-4a9c-aaec-90eeb0b4975b GET /v1/drugs/7d044a56-11e6-4a9c-aaec-90eeb0b4975b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1612134000000,\"rev\":1692866936000}",
"nregistro": "1201476001",
"substance": "Crizanlizumab"
}See everything about crizanlizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.